血清PSA联合Gleason评分与临床分期预测前列腺癌核素骨显像的影响分析

Impact Analysis of Serum PSA Combined Gleason Score and Clinical Stage of Prostate Cancer Bone Scintigraphy to Predict

目的 探究血清PSA联合Gleason评分与临床分期预测前列腺癌素骨显像结果关系。方法 随机选取2010年3月至2014年3月我院收治的前列腺癌患者117例,根据血清PSA与Gleason评分,对比各不同临界值的NPV、PPV,并预测分析骨显像结果。结果 PSA0-10 ng/m L、Gleason评分〈8分患者,PPV、NPV分别为71%、100%;PSA〉100 ng/m L/Gleason评分〉7分患者,NPV、PPV分别为42%、93%,提示血清PSA水平与Gleason评分及临床分期,都是前列腺癌骨显像的独立预测因子。结论 在诊疗上,对T1、T2分期患者行ECT骨显像,可降低治疗反应,而T3、T4期患者,骨转移已经发生。

Objective To explore the serum PSA combined Gleason score and clinical stage of prostate cancer hormone predict bone imaging relationship. Methods The patients were randomly selected 117 cases of prostate cancer from March 2010 to March 2014 in our hospital, according to serum PSA and Gleason score, comparing the different threshold NPV, PPV, and predictive analysis bone imaging.Results PSA0-10 ng/mL, Gleason score less than 8 minutes patients, PPV, NPV were 71%, 100%; PSA greater than 100 ng/mL/Gleason score greater than 7 points patient, NPV, PPV 42%, 93%, suggesting that serum PSA level and Gleason score and clinical stage, prostate cancer is an independent predictor of bone scintigraphy.Conclusion In the treatment of T1, T2 stage underwent ECT bone imaging, can reduce treatment response, and T3, T4 patients with bone metastasis has occurred.